No Data
No Data
Fuan Pharmaceutical (300194.SZ) announced its 2023 annual results, with net profit of 232 million yuan, an increase of 13.32%
Fuan Pharmaceutical (300194.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 2...
Fuan Pharmaceutical (300194.SZ): Midazolam hydrochloride obtained approval notice for the marketing application of chemical raw materials
Fuan Pharmaceutical (300194.SZ) announced that Fuan Pharmaceutical Group Chongqing Bosheng Pharmaceutical Co., Ltd. (“Bosheng Pharmaceutical”), a wholly-owned subsidiary of the company, recently received a chemical ingredient marketing application approval notice issued by the State Drug Administration. The name of the ingredient is midazolam hydrochloride, which is mainly used for pre-anesthetic administration, induction and maintenance of general anesthesia, adjuvant medication, diagnostic or therapeutic procedures during local anesthesia (such as cardiovascular radiography, cardiac arrhythmia, bronchoscopy, gastrointestinal endoscopy, etc.) Sedation, ICU patient sedation.
Fuan Pharm Unit's Hemorrhage Drug Gets Registration Certificate From China's Drug Regulator
Fuan Pharm (SHE:300194) said China's National Medical Products Administration (NMPA) issued a drug registration certificate for Nimodipine Tablets, according to a Monday filing on the Shenzhen Stock E
Fuan Pharmaceutical (300194.SZ): Nimergoline tablets received a drug registration certificate
Gelonghui, April 7 | Fu'an Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. recently received a drug registration certificate issued by the State Drug Administration. Drug name: nimegoline tablets. Nimergoline tablets are suitable for improving low motivation due to the sequelae of a stroke; they are also suitable for vascular dementia. In particular, during early treatment, they improve cognition, memory, etc., and can reduce the severity of the disease.
Fuan Pharmaceutical (300194.SZ): Does not produce radiation protection drugs
Gelonghui, March 28 | Fuan Pharmaceutical (300194.SZ) said on the investor interactive platform that the company currently does not produce radiation-proof drugs, and that the company will keep an eye on diseases and radiation lesions that may be caused to humans by draining nuclear sewage into the sea.
Express News | Fuan Pharmaceutical said on an interactive platform on March 11 that the company currently does not produce diet drugs.
No Data